Our ability to accurately select patients for treatments that target specific molecular abnormalities contained within an individual’s cancer cells will be essential for the practice of modern hematology/oncology. Yet, as physicians and scientists we remain frustrated by our inability to predict who will respond to treatment and who will not.
